Indian stocks: Visit www.stage2stocks.com →

InflaRx N.V.

Stage 3 · Topping · week 3

As of Oct 22, 2026, InflaRx is in Stage 3, the topping phase, now in week 3 (since Oct 2, 2026). It closed at $1.53, 44.2% below its 52-week high and below its 200-day average, which is rising.

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. More about the company

$1.53
-1.29% today
$225M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is IFRX early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 15w
S4 13w
S2 17w
S4 13w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S3 8w → S4 15w → S1 9w → S4 13w → S1 4w → S2 3w → S3 3w → S4 6w → S1 1w → S2 17w → S3 5w → S4 7w → S1 3w → S4 12w → S1 8w → S2 4w → S3 7w → S4 13w → S1 2w → S2 12w → S3 5w → S2 5w → S3 3w current
Total tracked: 165 weeks across 23 stage runs.

IFRX among Biotechnology149th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…149IFRXStage 3 · wk 364−21.9%
vs 52W High
-44.2%
$0.83 lo$2.74 hi
44.2% below 52W high, weakening from peak
The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.
Stage Maturity
Week 3
1w13w26w
Week 3, early distribution
How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.
vs 200 DMA
-5.5%
200 DMA: $1.62 · rising
Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.
Rel Volume
0.52x
vs 50-day avg
Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-21.9%
3M
-12.1%
6M
-1.9%
YTD
+40.4%
1Y
+12.5%
Scan Membership
Breakout Watch
Latest: 2024-10-29
12 appearances in last 60 days. First seen: 2018-10-16.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S3
Wk 3 · Vol 0.52x
2026-10-21S3
Wk 3 · Vol 0.89x
2026-10-20S3
Wk 3 · Vol 0.92x
2026-10-19S3
Wk 3 · Vol 3.73x
2026-10-16S3
Wk 3 · Vol 2.10x
2026-10-15S3
Wk 2 · Vol 0.75x
2026-10-14S3
Wk 2 · Vol 0.79x
2026-10-13S3
Wk 2 · Vol 0.49x
2026-10-12S3
Wk 2 · Vol 0.63x
2026-10-09S3
Wk 2 · Vol 0.98x
2026-10-08S3
Wk 1 · Vol 1.52x
2026-10-07S3
Wk 1 · Vol 0.60x
Moving averages & range
50 DMA
$1.92
200 DMA
$1.62
52W High
$2.74
52W Low
$0.83
5D Low
$1.32
Resistance levels (recent highs)
20d High
$1.89
60d High
$2.46
120d High
$2.74
250d High
$2.74
Next resistance
+23.5%
to 20d High
ROE
-38.5%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 1.4

InflaRx: quick answers

What stage is InflaRx in?

As of Oct 22, 2026, InflaRx (IFRX) is in Stage 3, the topping phase. It entered Stage 3 on Oct 2, 2026 and is in week 3. What the four stages mean

Is InflaRx in an uptrend?

Its uptrend has stalled. InflaRx is in Stage 3, the topping phase that follows an advance. It trades 5.5% below its 200-day average, which is rising.

How far is InflaRx from its 52-week high?

InflaRx closed at $1.53 on Oct 22, 2026, 44.2% below its 52-week high of $2.74. Its 52-week low is $0.83.

How has InflaRx performed over the past year?

As of Oct 22, 2026, InflaRx is up 12.5% over the past year and up 40.4% so far in 2026.

Which sector and industry is InflaRx in?

InflaRx is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering from early septic organ dysfunction, biological proof of concept was established, demonstrating its unique C5a blocking ability and selectivity; Izicopan, an oral, low molecular weight drug to target C5aR with high affinity and selectivity has completed completing Phase 2a trials; and IFX002, an advancement of vilobelimab technology, which is in preclinical development for the treatment of chronic inflammatory indications. It has co-development agreement with Staidson (Beijing) BioPharmaceuticals Co., Ltd.; Cell line sales agreement with Catalent Pharma Solutions LLC; Clinical Trial Collaboration Agreement with the U.S. DHHSs, Administration for Strategic Preparedness and Response (ASPR), BARDA and PPD Development, L.P., or PPD. InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. The company was founded in 2007 and is headquartered in Jena, Germany.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.